• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Sonus meets with FDA on EchoGen

Article

It could be as long as 10 months before Sonus Pharmaceuticals gets its EchoGen ultrasound contrast agent on the market, as it moves to comply with the Food and Drug Administration’s concerns about the agent’s new drug application (NDA). Sonus

It could be as long as 10 months before Sonus Pharmaceuticals gets its EchoGen ultrasound contrast agent on the market, as it moves to comply with the Food and Drug Administration’s concerns about the agent’s new drug application (NDA). Sonus of Bothell, WA, met with the FDA on April 27 to discuss the NDA after receiving a not-approvable letter for EchoGen in February (SCAN 3/18/98).

Sonus reported that it plans to submit an amendment to EchoGen’s NDA in the next two to four months to respond to the FDA’s concerns regarding the manufacturing processes for EchoGen, including chemistry and analytical methods validation, as well as the company’s analysis of animal and clinical data in the application. Once Sonus submits the amendment, the FDA could take up to six months to review it before rendering a decision.

Related Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.